Mackenzie Financial
ANIK icon

Mackenzie Financial’s Anika Therapeutics ANIK Stock Holding History

Mackenzie Financial’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,484
Closed -$413K – 1707
2025
Q1 		$413K Buy
27,484
+13,436
+96% +$224K ﹤0.01% 1259
2024
Q4 		$231K Buy
+14,048
New +$277K ﹤0.01% 1498

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Mackenzie Financial's ANIK Position: Q2 2025 in Review

Mackenzie Financial sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 27,484 shares — an estimated $413K sold.

Mackenzie Financial first reported a position in ANIK in Q4 2024 and held it in 2 quarters. The position peaked at $413K in Q1 2025. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • Mackenzie Financial reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mackenzie Financial sold 27,484 Anika Therapeutics shares in Q2 2025, an estimated $413K.
  • Mackenzie Financial first reported a position in Anika Therapeutics in Q4 2024 and held it in 2 quarters.
  • Mackenzie Financial's Anika Therapeutics position peaked at $413K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.